PharmaNet Launches New Brand Identity
News Nov 25, 2010
The new branding unifies PharmaNet’s messaging across all of its subsidiaries and services, and clearly articulates the entire Company’s commitment to client service around the world. PharmaNet has the global reach and experience to execute clinical development programs from small local projects to large global programs with a custom-fit philosophy that provides a personalized approach to client service.
PharmaNet’s new brand identity has already appeared in a pre-launch advertising campaign running in digital and print industry publications. It will be formally launched at two upcoming industry events, the 2010 American Association of Pharmaceutical Scientists (AAPS) Annual Meeting in New Orleans, Louisiana, from November 14-18 and the 9th Annual Partnerships in Clinical Trials Conference in Vienna, Austria, from November 16-19.
“The trusted PharmaNet name now serves as the umbrella brand for all our global clinical development service offerings, from bioequivalence and bioanalytical services to Phase I – IV programs,” said Jeffrey P. McMullen, Chief Executive Officer, PharmaNet.
“We have taken on this initiative to strengthen and modernize our brand into one voice,” Mr. McMullen explained. “This investment in PharmaNet’s future demonstrates commitment to our clients and provides a solid foundation for our continued expansion of services, geographies, and capabilities.”
The cholesterol-lowering drugs called statins have demonstrated substantial benefits in reducing the risk of heart attacks and strokes caused by blood clots (ischemic strokes) in at-risk patients. Since statins are associated with a low risk of side effects, the benefits of taking them outweigh the risks, according to a scientific statement from the American Heart Association that reviewed multiple studies evaluating the safety and potential side effects of these drugs.READ MORE
18th International Conference on Pharmaceutics & Novel Drug Delivery Systems
May 27 - May 28, 2019